Business Wire

Business Wire, a wholly owned subsidiary of Berkshire Hathaway, is the global market leader in commercial news distribution.

Recent Articles By The Author

His Holiness Pope Francis Addresses Time Inc.'s 2016 Fortune/Time Global Forum At The Vatican

His Holiness Pope Francis Addresses Time Inc.'s 2016 Fortune/Time Global Forum At The Vatican

On December 2 and 3, Time Inc.'s (NYSE:TIME) 2016 Fortune/Time Global Forum convened select global Fortune 500 CEOs, members of the Time 100 and nonprofit, academic, religious and labor leaders to address the need for a...

Call Of Duty World League (CWL), Presented By PlayStation®4, Kicks-off New Season With Invitational Tournament At PlayStation Experience (PSX)

Call Of Duty World League (CWL), Presented By PlayStation®4, Kicks-off New Season With Invitational Tournament At PlayStation Experience (PSX)

Today, the Call of Duty® World League, Presented by PlayStation®4, revealed plans for the upcoming season.

Seattle Genetics Presents Phase 1b Data From Vadastuximab Talirine (SGN-CD33A; 33A) In Combination With Standard Of Care In Frontline Acute Myeloid Leukemia At ASH Annual Meeting

Seattle Genetics Presents Phase 1b Data From Vadastuximab Talirine (SGN-CD33A; 33A) In Combination With Standard Of Care In Frontline Acute Myeloid Leukemia At ASH Annual Meeting

Seattle Genetics, Inc. (NASDAQ: SGEN), a global biotechnology company, today highlighted phase 1b data evaluating vadastuximab talirine (SGN-CD33A; 33A) in combination with the frontline standard of care regimen for...

Seattle Genetics Presents Data From Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Diffuse Large B-cell Lymphoma At ASH Annual Meeting

Seattle Genetics Presents Data From Phase 2 Study Evaluating ADCETRIS® (Brentuximab Vedotin) In Frontline Diffuse Large B-cell Lymphoma At ASH Annual Meeting

Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today presented data from a phase 2 clinical trial evaluating ADCETRIS (brentuximab vedotin) combination therapy in frontline diffuse large...